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Abstract
Type 1 diabetes and insulinoma can co-occur in pediatric patients and may present with episodes of hypo-and hyperglycemia, significant glycemic variability,
and weight gain. Surgical resection leads to development of fulminant diabetes.
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I N T RO DU CT ION

We report the co-occurrence of insulinoma and type 1 diabetes (T1D) in the youngest known patient—the presence
of opposing pathologies obscured typical clinical presentations. Development of fulminant T1D was anticipated
with insulinoma resection, and as such, T1D-related surgical complications were prevented. Longitudinal assessment and data re-evaluation are critical.
Insulinomas are well-
differentiated pancreatic
neuroendocrine tumors (NET) and are rare causes

of hypoglycemia, especially in children.1 Type 1 diabetes (T1D) has been associated with a prodrome of
hypoglycemia, attributable to delayed insulin secretion.2,3 Natural history studies have elucidated three
stages of T1D that begin with pancreatic autoantibody
positivity in the setting of euglycemia.4 Progression to
stage 2 occurs when there is evidence of dysglycemia
in the absence of symptomatology. Stage 3 represents
symptomatic hyperglycemia. Patients progress with
variable speed, dictated by the interaction of genetics
and environment.4

Sriya Subramani has since relocated to Seattle Children's Hospital to continue her training.
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We describe the case of an adolescent male who presented with acute altered mental status secondary to hyperinsulinemic hypoglycemia. Evaluation revealed both
stage 2 T1D and an insulinoma. This case is the youngest
described co-occurrence of T1D and insulinoma and highlights the importance of thorough data evaluation to ensure that antagonist processes do not mask the complete
diagnosis. This case also demonstrates beta-cell destruction and inflammation adjacent to neuroendocrine proliferation, which may have implications for the prevention
and treatment of T1D.

2 | C A S E HISTORY /
E X A M I NAT I ON
A 17-year-old previously healthy male presented to the
emergency department due to acute altered mental status. Initial laboratories demonstrated a low blood glucose
(BG) of 1.8 mmol/L (reference range 3.6–7.7 mmol/L),
and he received 1 ml/kg intravenous 50% dextrose solution (D50W). Repeat BG twelve minutes later was
5.4 mmol/L. BG continued to rise for three hours, peaking at 12.1 mmol/L. Mental status improved after dextrose
administration.
His past medical history is pertinent for attention deficit hyperactivity disorder for which he took
dextroamphetamine-
amphetamine. Family history is
relevant for autoimmune thyroid disease in his mother
and father. Initial workup included thyroid studies and
urine drug screen. Thyroid-stimulating hormone (TSH)
was normal. Urine drug screen returned presumptive positive for tetrahydrocannabinol (THC), and he
endorsed using marijuana 48 hours prior to presentation. A sulfonylurea screen drawn at presentation was
negative.

of 1 ml/kg D50W, and dextrose-containing fluids were titrated to maintain euglycemia overnight. After initiation
of a general diet, BGs were assessed every two hours and
ranged from 2.9–9.1 mmol/L.
Pancreatic autoantibodies (insulin, IgG Islet Cell, Islet
Antigen 2, Glutamic Acid Decarboxylase) were obtained
due to suspicion of insulin autoimmune syndrome or
T1D, given the evidence of reactive hyperglycemia, generous post-prandial blood glucoses, and family history of
autoimmune thyroid disease.5 All pancreatic antibody levels returned positive, and he was given a diagnosis of stage
1 type 1 diabetes. Abdominal ultrasound was obtained to
assess for presence of a pancreatic mass and was read as
normal.
Glucagon administration, self-monitoring of blood glucose (SMBG) teaching, and nutrition education were completed, and he was discharged after three days.
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OUTCOME AND FOLLOW- U P

He subsequently enrolled in TrialNet Pathway to
Prevention and tested positive for five pancreatic autoantibodies (islet cell antibody—ICA, glutamic acid decarboxylase antibody 65kd—GAD65, islet cell autoantibody
512—ICA512, micronized insulin autoantibody—mIAA,
and zinc transporter 8—ZnT8).6 See Table 2 for a summary of all islet antibodies obtained over the clinical
course.
He was instructed to continue SMBG three times per
day, which demonstrated modest hyperglycemia with hypoglycemia predominance (Table 3). Approximately three

3 | DI F F E R E N T IAL DIAG N OSIS,
I N VE ST I GATION S, AN D IN IT IAL
T RE AT M E NT
He was admitted and made nil per os (NPO). BGs were
monitored every 1–2 h (Figure 1). His BG dropped to
2.1 mmol/L ten hours into the fast. A critical sample
was obtained which was notable for a total insulin level
of 158.35 pmol/L (reference range 18.06–172.93 pmol/L)
and c-peptide level of 1.09 nmol/L (0.36–1.46 nmol/L),
both inappropriately elevated relative to his low BG. Beta-
hydroxybutyrate was suppressed. Adrenocorticotrophic
hormone (ACTH), cortisol, growth hormone, and the remainder of critical sample laboratories were appropriate
for clinical context (Table 1). He received a second dose

F I G U R E 1 This figure demonstrates the evolution in response
to stimuli during his hospitalization and shows hypoglycemia
with fasting as well as reactive hyperglycemia. Star signifies when
patient was given D50. Circle signifies start of NPO. Square signifies
second D50 administration with start of D10 infusion
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T A B L E 1 Inclusive list of all laboratory tests sent as part of the
critical sample (when plasma glucose was 2.0 mmol/L) and their
corresponding reference ranges
Laboratory test

Patient's value

Reference range

ACTH

5.06 pmol/L

1.32–12.10 pmol/L

Anion Gap

15 mmol/L

<17 mmol/L

Acylcarnitine profile

Normal profile

Normal profile

Ammonia

19 umol/L

21–50 umol/L

Bicarbonate

23 mmol/L

22–29 mmol/L

Beta-hydroxybutyrate

0.3 mmol/L†

0.0–0.3 mmol/L

C-peptide

1.09 nmol/L*

0.36–1.46 nmol/L

Cortisol

311.74 nmol/L

74.49–
507.62 nmol/L
(random timed)

Free fatty acids

0.8 mmol/L†

*No reference for
<18yo

Growth Hormone

5.69 ug/L

0.08–10.80 ug/L

Insulin

158.35 pmol/L*

0.56–172.93 pmol/L

Lactate

0.6 mmol/L

0.5–2.2 mmol/L

Plasma amino acids

Normal profile

Normal profile
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months after hospital discharge, the patient underwent
an oral glucose tolerance test (OGTT) (Figure 2), which
demonstrated a 1-h BG of 12.0 mmol/L and a 2-h BG of
11.1 mmol/L, indicative of significant impairment in glucose tolerance (stage 2 T1D) and imminent risk to progress to clinically evident T1D.7
Over the next month, the patient had significant
weight gain. He discontinued SMBG, so a continuous
glucose monitor (CGM) was placed. CGM demonstrated
patterns of prolonged fasting hypoglycemia juxtaposed
with hyperglycemia (Figure 3). HbA1c increased from
28 mmol/mol (4.7%) at presentation to 37 mmol/mol
(5.5%) (reference 29–42 mmol/mol). Abdominal magnetic resonance imaging (MRI) was obtained due to
suspicion that the patient's dysglycemia was not solely
attributable to the beta-cell dysfunction that can be noted
in stage 2 T1D.2,3,8 MRI demonstrated a 1.9 × 1.3 cm
solid lesion in the tail of the pancreas (Figure 4A-D).
Compared to the normal pancreatic parenchyma, the lesion showed low signal intensity (dark) on T1W images
and high signal intensity (bright) on T2W images. After
IV contrast enhancement using gadolinium, there was
decreased contrast differentiation between the lesion
and the normal parenchyma in both arterial and venous
phases.

Values denoted with an asterix are inappropriately elevated relative to the
clinical context (ie, hypoglycemia), and the values denoted with a † are
relatively low for the clinical context. All other values are within normal
limits.

TABLE 2

|

Islet autoantibody status

Islet antibody

Date obtained

Patient's value

Reference range

Interpretation

Insulin antibody*

5/14/2020

0.7 U/ml

0–0.4 U/L

Positive

mIAA (micronized insulin) †

6/3/2020

0.038

≤0.010

Positive

mIAA †

7/24/2020

0.054

≤0.010

Positive

Insulin antibody‡

3/19/2021

28.6

0–0.4 U/L

Positive

Islet cell antibody (IgG)*

5/14/2020

1:16

<1:4

Positive

Islet cell antibody†

6/3/2020

160

<10

Positive

Islet cell antibody†

7/24/2020

320

<10

Positive

Islet cell antibody (IgG) ‡

3/19/2021

<1:4

<1:4

Negative

Glutamic acid decarboxylase*

5/14/2020

>250 IU/ml

0.0–5.0 IU/ml

Positive

Glutamic acid decarboxylase†

6/3/2020

663

≤20

Positive

Glutamic acid decarboxylase†

7/24/2020

760

≤20

Positive

Glutamic acid decarboxylase‡

3/19/2021

>250 IU/ml

0.0–5.0 IU/ml

Positive

Islet antigen 2*

5/14/2020

>120 U/ml

0.0–7.4 U/ml

Positive

ICA512/IA−2H†

6/3/2020

382

≤5

Positive

ICA512/IA−2H†

7/24/2020

385

≤5

Positive

Islet antigen 2‡

3/19/2021

>120 U/ml

0.0–7.4 U/ml

Positive

ZnT8†

6/3/2020

0.3310

≤0.020

Positive

ZnT8†

7/24/2020

0.3630

≤0.020

Positive

ZnT8‡

3/19/2021

>500

0–15 KU/ml

Positive

All 4 antibodies sent during the initial inpatient admission were positive and are denoted with *. The second and third sets were obtained as part of TrialNet
and are denoted with †. ‡ denotes testing sent 4 months after surgical resection of mass and initiation of insulin therapy. The only antibody that became
negative after surgical resection was Islet Cell IgG.
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He subsequently underwent endoscopic fine-needle
biopsy. Cytopathology confirmed the presence of a
somatostatin-
receptor 2a (SSTR2a) positive, well-
differentiated NET (KI-
67 proliferation index 13.6%)
lesion. Serum chromogranin A, pancreastatin, and
gastrin levels were normal. Serotonin was slightly elevated (1.61 umol/L, reference 0.28–
1.14 umol/L).
Pre-
biopsy laboratories demonstrated fasting hyperglycemia (17.7 mmol/L) with elevated fasting insulin
(341.0 pmol/L) and c-peptide levels (1.39 nmol/L) without evidence of ketosis.
He underwent T1D education, as it was anticipated
that he would develop insulinopenia after removal of his
endogenous insulin source. The patient developed persistent hyperglycemia and ketonuria without acidosis
within five hours of surgical resection. C-peptide level
was inappropriately low (0.33 nmol/L) with hyperglycemia (17.0 mmol/L). Insulin therapy was initiated, and he
was discharged on a total daily insulin dose of 0.6 U/kg/
day. One-month post-resection, his HbA1c was 50 mmol/
mol (6.7%) on 0.7 U/kg/day. Non-tumorous peripancreatic tissue demonstrated classic histologic findings of
T1D, including inflammatory infiltration around the residual islets (Figure 5A-J).9 Quantitative evaluation of 50
islets revealed that 11/50 (22%) showed insulitis, 50/50
(100%) expressed glucagon, and 6/50 (12%) expressed
insulin.
Genetic testing was completed via the Detect
Hereditary Pancreatic Cancer Program, which includes
MEN1, NF1, VHL, TSC1, and TSC2. Testing returned
negative except a heterozygous variant of unknown significance in RECQL4 c.2069 C>T. Human leukocyte antigen (HLA) genotyping demonstrated the presence of one
high-risk T1D class 2 haplotype, DR4, in the context of
six total risk-associated class 2 alleles (five unique alleles,
with two copies of the DQA1*03:01 allele). There were
no protective DRB1, DQB1, or DPB1 alleles present.10-12
(Supplemental Table 1).
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DISC USSION

This previously healthy 17-year-old male met the criteria
for Whipple's triad [signs/symptoms of hypoglycemia, low
plasma glucose, resolution of signs/symptoms of hypoglycemia after hypoglycemia correction].13 The differential
diagnosis for hypoglycemia in an adolescent is broad and
falls into many overarching categories including metabolic

F I G U R E 2 Oral glucose tolerance test. The patient
demonstrated significant glucose intolerance to 75 g glucola OGTT.
The 2-hour blood glucose value of 11.1 mmol/L was at the 2-h
diagnostic cut point for diabetes mellitus and is depicted by the
horizontal line

T A B L E 3 SMBG readings from hospital discharge (May 2020)
to second clinic follow-up (September 2020)
Average BG (mmol/L)

4.7 mmol/L

Coefficient of variation

36%

Percent of BG below 3.0 mmol/L

10%

Percent of BG between 3.0 −3.9 mmol/L

31%

Percent of BG between 10–13.9 mmol/L

2%

Percent of BG above 13.9 mg/dl

0%

This reflects a total of 94 SMBG readings. Adherence to SMBG declined over
time, initially testing 4–5 times per day but then only testing with symptoms.
Only one blood glucose value was obtained between the beginning of
August 2020 and the middle of September 2020, which was 5.3 mmol/L.
Subsequently, the decision to begin CGM monitoring was made.

F I G U R E 3 Preoperative CGM values. Curve represents glucose
frequency distribution by time. Median values with the IQR are
plotted on graph. The patient's average CGM reading for the
42 days prior to surgery was 7.9 mmol/L with a predicted HbA1c
of 50 mmol/mol (6.7%). 19.9% of CGM glucoses were less than
3.3 mmol/L, with 5% time less than 3.0 mmol/L. 26% of values were
above 10 mmol/L, with almost 10% of values above 13.9 mmol/L.
This is an aggregate of 11,087 CGM data points

SUBRAMANI et al.

  

disorders, drugs, critical illness, hormone deficiency, and
endogenous hyperinsulinism.14
The patient's insulin secretagogue screen returned negative, and while his urine drug screen returned presumptive
F I G U R E 4 A-D Non-contrast axial
MRI of the pancreas (A & B) showed a
pancreatic tail mass (arrow). It showed
low signal intensity on T1W (FLASH
sequence) image (A) and high signal
intensity on T2W (HASTE) (B) compared
to normal parenchyma. After intravenous
gadolinium, the lesion showed less
conspicuity in both arterial (C) and
venous (D) phases

F I G U R E 5 A-F Panels A-D represent
a peritumoral islet with insulitis.
Panel A is the H&E stain. Panel B is
a CD3 immunostain demonstrating
approximately 60 infiltrating T cells.
Panels C &D are glucagon and insulin
stains, respectively. Panels E (H & E)
and F (CD3 immunostain) demonstrate
significant insulitis

|
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positive for THC, there is no literature to suggest that THC
induces hypoglycemia. Exogenous insulin administration
can induce hypoglycemia; however, the insulin and c-
peptide levels both returned relatively elevated.

(A)

(B)

(C)

(D)

(A)

(B)

(C)

(D)

(E)

(F)
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F I G U R E 6 Demonstration of inflammation within the
insulinoma. CD3-stained image demonstrating T cells lightly
dispersed throughout the tumor with accentuation at the edge of
the tumor

Critical illness and hormone deficiency secondary to
inborn errors of metabolism or congenital defects were
unlikely based on the patient's previous well-appearing
clinical picture and initial laboratory findings. It is important to note that this patient does not fit a clinical picture
consistent with adrenal insufficiency, as the only known
reports of patients with stage 3 T1D presenting with hypoglycemia are those with concurrent primary adrenal
insufficiency.15,16
The evaluation led to the diagnosis of hyperinsulinism,
which can occur via a multitude of etiologies including insulinoma, insulin autoimmune syndrome, and functional
beta-cell disorders (including early-stage T1D).2,3,5 It was
important to assess for insulin antibodies that might be
present in insulin autoimmune syndrome, and given the
family history and presence of reactive hyperglycemia,
it was prudent to obtain multiple islet autoantibodies simultaneously in the event the insulin antibody was positive. After determining that the hypoglycemia was more
profound than expected with a T1D prodrome, it was
necessary to obtain more sensitive imaging to screen for
insulinoma as this was not detected on initial ultrasound,
specifically noted to have low sensitivity for pancreatic
mass.17 The discovery of multiple pancreatic autoantibodies, in conjunction with his OGTT and CGM data, led to
two antagonistic diagnoses that each somewhat masked
the other.
NET are exceedingly rare in the pediatric population,
with an estimated incidence of 2.8 per 1,000,000.18 T1D
is much more common, with an incidence of approximately 22 per 100,000 in the United States.19 Insulinoma
masking the diagnosis of T1D has only been documented twice previously, in a 71-year-old woman and

a 49-year-old man, making our patient the youngest described.20 Pancreatic NET is observed with increasing
frequency in genetic syndromes including multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome,
neurofibromatosis type 1, and tuberous sclerosis but so
far our patient has tested negative for these associated
conditions.21
Beta-
cell destruction adjacent to neuroendocrine
proliferation may suggest that the T1D antigen is expressed on the native beta cells only and not the insulin-
producing NET cells. Our patient's rising blood glucoses
pre-operatively could represent the natural history of
T1D or provide evidence that there was autoimmune
attack on the tumor. Inflammation and cancer are intimately linked, but there is anecdotal evidence that
insulinomas do not demonstrate T-cell infiltration.20,22
However, CD3+ T cells were noted to have infiltrated
the adjacent insulinoma (Figure 6). Determination of
the antigenic target of the islet T cells and the tumoral T
cells may play a role in understanding more of the pathogenesis of T1D.

6
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CONC LUSION

This case highlights the utility of investigating multiple pancreatic autoantibodies in a pediatric patient
with hyperinsulinemic hypoglycemia as this prevented
us from erroneously diagnosing him with insulin autoimmune syndrome if only insulin antibody had been
ordered and returned positive. Instead, this led to the
diagnosis of dual processes that each needed to be addressed. Diabetes education was able to be initiated pre-
operatively and awareness of impending hyperglycemia
prevented development of ketoacidosis, which may have
been difficult to distinguish from a post-operative complication. Co-existence of proliferative and destructive
processes in a patient at high genetic risk to develop T1D
may lead to further understanding of the pathogenesis of
T1D. To conclude, the possibility of co-existing T1D and
insulinoma, although exceedingly rare, should be considered when early-stage T1D is predominated by hypoglycemia with weight gain as it will significantly impact
management of both processes.
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